{"DataElement":{"publicId":"3855563","version":"1.1","preferredName":"Acute Leukemia Or Chronic Myelogenous Leukemia Morphologic Response Status","preferredDefinition":"Text term to describe the acute leukemia or chronic myelogenous leukemia disease status based on morphologic evaluation.","longName":"ALCML_MORPH_RESP_ST","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"3853604","version":"1","preferredName":"Acute Leukemia Or Chronic Myelogenous Leukemia Morphologic Response","preferredDefinition":"A clonal (malignant) hematopoietic disorder affecting the bone marrow and the peripheral blood.  The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts).  According to the type of blasts present, acute leukemias are classified as acute myeloid leukemia (AML) and precursor lymphoblastic or acute lymphoblastic leukemia (ALL)._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals.  Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and imatinib therapy delay disease progression and prolong overall survival._The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression._A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample._Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"3853602v1.0:3853589v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"3853602","version":"1","preferredName":"Acute Leukemia Or Chronic Myelogenous Leukemia, BCR-ABL1 Positive Response","preferredDefinition":"A clonal (malignant) hematopoietic disorder affecting the bone marrow and the peripheral blood. The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts). According to the type of blasts present, acute leukemias are classified as acute myeloid leukemia (AML) and precursor lymphoblastic or acute lymphoblastic leukemia (ALL).:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and imatinib therapy delay disease progression and prolong overall survival.:The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.","longName":"C9300:C37998:C3174:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Leukemia","conceptCode":"C9300","definition":"A clonal (malignant) hematopoietic disorder with an acute onset, affecting the bone marrow and the peripheral blood.  The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3CAB6C0-9770-2EEB-E040-BB89AD431DF6","latestVersionIndicator":"Yes","beginDate":"2013-08-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-12","modifiedBy":"ONEDATA","dateModified":"2013-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3853589","version":"1","preferredName":"Morphologic Finding Evaluation","preferredDefinition":"A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.:Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"C35867:C25214","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Finding","conceptCode":"C35867","definition":"A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Evaluation","conceptCode":"C25214","definition":"Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3CB76BD-D0D5-2626-E040-BB89AD436DA7","latestVersionIndicator":"Yes","beginDate":"2013-08-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-12","modifiedBy":"ONEDATA","dateModified":"2013-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E3CAB6C0-977E-2EEB-E040-BB89AD431DF6","latestVersionIndicator":"Yes","beginDate":"2013-08-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-12","modifiedBy":"KNABLEJ","dateModified":"2017-08-23","changeDescription":"8/23/17 jk added registration status and CSI per Round 5 finalization task.  8/13/13 mc Created for CRF Harmonization per request by Response WG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3854974","version":"1.1","preferredName":"Acute Leukemia/CML Morphologic Finding Response Status","preferredDefinition":"A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample._The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression._A condition or state at a particular time.","longName":"ALCML_MORPH_RESP_ST","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"75","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Morphologic Complete Remission with Incomplete Blood Count Recovery (CRi)","valueDescription":"Morphologic Complete Remission with Incomplete Blood Count Recovery ","ValueMeaning":{"publicId":"3854971","version":"1","preferredName":"Morphologic Complete Remission with Incomplete Blood Count Recovery ","longName":"3854971","preferredDefinition":"The disappearance of all cells with morphologic characteristics of cancer, accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Complete Remission with Incomplete Blood Count Recovery","conceptCode":"C123596","definition":"The disappearance of all cells with morphologic characteristics of cancer, accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-86DA-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A420C30-612C-73C6-E053-F662850A29F9","beginDate":"2013-08-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-28","modifiedBy":"ONEDATA","dateModified":"2017-09-28","deletedIndicator":"No"},{"value":"Morphologic Leukemia Free State","valueDescription":"Morphologic Finding Leukemia Absent State","ValueMeaning":{"publicId":"3854975","version":"1","preferredName":"Morphologic Finding Leukemia Absent State","longName":"3854975","preferredDefinition":"A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.: A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.: Not existing in a specified place at a specified time.: State; the way something is with respect to its main attributes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Finding","conceptCode":"C35867","definition":"A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Absent","conceptCode":"C48190","definition":"Not existing in a specified place at a specified time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"State","conceptCode":"C25687","definition":"The way something is with respect to its main attributes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-874A-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A420C30-6136-73C6-E053-F662850A29F9","beginDate":"2013-08-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-28","modifiedBy":"ONEDATA","dateModified":"2017-09-28","deletedIndicator":"No"},{"value":"Morphologic Relapse","valueDescription":"Morphologic Finding Recurrent Disease","ValueMeaning":{"publicId":"3854968","version":"1","preferredName":"Morphologic Finding Recurrent Disease","longName":"3854968","preferredDefinition":"A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.: The return of a disease after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Finding","conceptCode":"C35867","definition":"A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-8691-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A420C30-614A-73C6-E053-F662850A29F9","beginDate":"2013-08-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-28","modifiedBy":"ONEDATA","dateModified":"2017-09-28","deletedIndicator":"No"},{"value":"Not Evaluable","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3153578","version":"1","preferredName":"Unevaluable","longName":"3153578","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93AC689E-5DB2-5D7A-E040-BB89AD430948","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-28","modifiedBy":"KUMMEROA","dateModified":"2023-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A420C30-6154-73C6-E053-F662850A29F9","beginDate":"2013-08-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-28","modifiedBy":"ONEDATA","dateModified":"2017-09-28","deletedIndicator":"No"},{"value":"Complete Remission (CR)","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"3854972","version":"1","preferredName":"Complete Remission","longName":"3854972","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-86FD-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Manually curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A420C30-615E-73C6-E053-F662850A29F9","beginDate":"2013-08-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-28","modifiedBy":"ONEDATA","dateModified":"2017-09-28","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A420C30-6168-73C6-E053-F662850A29F9","beginDate":"2014-11-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-28","modifiedBy":"ONEDATA","dateModified":"2017-09-28","deletedIndicator":"No"},{"value":"Relapse","valueDescription":"Relapse","ValueMeaning":{"publicId":"2857244","version":"1","preferredName":"Relapse","longName":"2857244","preferredDefinition":"The return of signs and symptoms of cancer after a period of improvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Relapse","conceptCode":"C18265","definition":"The return of signs and symptoms of cancer after a period of improvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66219F23-0990-8382-E040-BB89AD432D5C","latestVersionIndicator":"Yes","beginDate":"2009-03-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-03-27","modifiedBy":"KUMMEROA","dateModified":"2023-11-17","changeDescription":null,"administrativeNotes":"2023.3.9 Added Alt VM per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A420C30-6172-73C6-E053-F662850A29F9","beginDate":"2014-11-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-28","modifiedBy":"ONEDATA","dateModified":"2017-09-28","deletedIndicator":"No"},{"value":"Refractory Disease","valueDescription":"Refractory Disease","ValueMeaning":{"publicId":"4571271","version":"1","preferredName":"Refractory Disease","longName":"4571271","preferredDefinition":"A disease that resists treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refractory Disease","conceptCode":"C39752","definition":"A disease that resists treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06FECA4E-7E2B-9714-E050-BB89AD432ED0","latestVersionIndicator":"Yes","beginDate":"2014-11-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-03","modifiedBy":"KUMMEROA","dateModified":"2023-03-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A420C30-617C-73C6-E053-F662850A29F9","beginDate":"2014-11-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-28","modifiedBy":"ONEDATA","dateModified":"2017-09-28","deletedIndicator":"No"},{"value":"Progressive Disease (PD)","valueDescription":"Progressive Disease","ValueMeaning":{"publicId":"2559908","version":"1","preferredName":"Progressive Disease","longName":"2559908","preferredDefinition":"Cancer that is increasing in scope or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B711-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"HARTLEYG","dateModified":"2014-10-10","changeDescription":"Manually Curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A420C30-6186-73C6-E053-F662850A29F9","beginDate":"2014-11-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-28","modifiedBy":"ONEDATA","dateModified":"2017-09-28","deletedIndicator":"No"},{"value":"Not Assessed","valueDescription":"No Assessment","ValueMeaning":{"publicId":"2768467","version":"1","preferredName":"No Assessment","longName":"2768467","preferredDefinition":"The non-affirmative response to a question.: Having determined the value, significance, or extent of.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25217","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"52C71733-4814-2BF1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-07-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A420C30-6190-73C6-E053-F662850A29F9","beginDate":"2013-08-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-28","modifiedBy":"ONEDATA","dateModified":"2017-09-28","deletedIndicator":"No"},{"value":"Partial Remission (PR)","valueDescription":"Partial Remission","ValueMeaning":{"publicId":"3951935","version":"1","preferredName":"Partial Remission","longName":"3951935","preferredDefinition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB155E17-C5B7-CEC3-E040-BB89AD4342C2","latestVersionIndicator":"Yes","beginDate":"2013-11-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A57F18F-BEF7-2B2A-E053-F662850AB5C3","beginDate":"2017-09-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-29","modifiedBy":"ONEDATA","dateModified":"2017-09-29","deletedIndicator":"No"},{"value":"Stable Disease (SD)","valueDescription":"Stable Disease","ValueMeaning":{"publicId":"2982985","version":"1","preferredName":"Stable Disease","longName":"2982985","preferredDefinition":"Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C991ADD-0176-711A-E040-BB89AD432C85","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F282269-B857-2503-E053-F662850AAA02","beginDate":"2019-08-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-02","modifiedBy":"ONEDATA","dateModified":"2019-08-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3865327","version":"1","preferredName":"Morphologic Finding Response Status","preferredDefinition":"A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.:The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.:A condition or state at a particular time.","longName":"C35867:C50995:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Finding","conceptCode":"C35867","definition":"A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4E2F160-F279-E72E-E040-BB89AD430752","latestVersionIndicator":"Yes","beginDate":"2013-08-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-26","modifiedBy":"ONEDATA","dateModified":"2013-08-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"5A420C30-6115-73C6-E053-F662850A29F9","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-28","modifiedBy":"HARTLEYG","dateModified":"2019-08-02","changeDescription":"9/29/17 tt Re-added Partial Response PV.  9/28/17 tt versioned VD to remove Partial response (PR) from PVs. 8/23/17 jk added registration status and CSI per Round 5 finalization task.   8/13/13 mc Created for CRF Harmonization per request by Response WG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2192345","version":"1","longName":"Data Standards","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3813676","version":"1","longName":"Response CRF","context":"NCIP"},{"publicId":"2859963","version":"1","longName":"Standard CRFs","context":"NCIP"}]},{"publicId":"5635300","version":"1","longName":"Case Report Form (CRF) Modules","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"3813675","version":"1","longName":"Response","context":"NCI Standards"}]},{"publicId":"7434158","version":"1","longName":"CTEP CDISC Harmonization","context":"CTEP","ClassificationSchemeItems":[{"publicId":"7590138","version":"1","longName":"CTEP CDISC Response","context":"CTEP"}]}],"AlternateNames":[{"name":"RS_RSORRES_MRPHRESP_CML","type":"CTEP CDISC CDE","context":"CTEP"}],"ReferenceDocuments":[{"name":"Morphologic status (Acute leu","type":"Preferred Question Text","description":"Morphologic status (Acute leukemia/CML)","url":null,"context":"NCI Standards"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Disease response:","url":null,"context":"Alliance"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Morphologic Status","url":null,"context":"Theradex"},{"name":"Prior Question Text","type":"Standard Alternate Question Text","description":"Morphologic Status (Acute Leukemia/CML)","url":null,"context":"NCI Standards"},{"name":"CTEP Text 1","type":"Alternate Question Text","description":"What was the CML morphologic response?","url":null,"context":"CTEP"},{"name":"CTEP Text 2","type":"Alternate Question Text","description":"CML morphologic response","url":null,"context":"CTEP"}],"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"5A421A50-8895-3799-E053-F662850A5DD1","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-28","modifiedBy":"CLOHNES","dateModified":"2022-10-21","changeDescription":"9/28/17 tt Versioned due to new VD version per Round 5 finalization task. 8/23/17 jk transferred context, U/L question, and added CSI, registration status per Round 5 finalization task.  8/14/13 mc Created per request by CRF Harmonization Response WG.","administrativeNotes":"10/21/22 added 1 alt name, 2 AQTs, 1 classification for the CTEP CDISC Harmonization project;","unresolvedIssues":null,"deletedIndicator":"No"}}